Current filters:

solanezumabEli Lilly

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J


Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

Lilly plans new trial of Alzheimer's hope solanezumab


US drug major Eli Lilly (NYSE: LLY) is planning to carry out an additional Phase III trial of its Alzheimer's…

Eli LillyNeurologicalPharmaceuticalResearchsolanezumab

Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial


Leading scientists at the USA's Washington University at St Louis have selected the first drugs to be…

BiotechnologyEli LillygantenerumabNeurologicalPharmaceuticalResearchRochesolanezumab

Mixed results with Eli Lilly Alzheimer's drug solanezumab, but investors pleased


US pharma major Eli Lilly (NYSE: LLY) yesterday reported detailed results from two Phase III studies…

BiotechnologyEli LillyNeurologicalPharmaceuticalResearchsolanezumab

Mixed news on Lilly's Alzheimer's drug solanezumab; Alimta patent upheld


US drug major Eli Lilly (NYSE: LLY) revealed last Friday that the primary endpoints, both cognitive and…

AlimtaEli LillyLegalNeurologicalNorth AmericaOncologyPatentsPharmaceuticalResearchsolanezumabTeva Pharmaceutical Industries

Alzheimer’s drug market to triple to $14.3 billion by 2020, says DR


The Alzheimer’s disease drug market will nearly triple over the next 10 years, increasing from $5.4…

bapineuzumabEli LillyGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalsolanezumab

Back to top